UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038186
Receipt number R000043527
Scientific Title Study of trans arterial chemo-embolization for primary or metastatic lung cancer
Date of disclosure of the study information 2019/10/04
Last modified on 2019/10/02 17:02:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of trans arterial chemo-embolization for primary or metastatic lung cancer

Acronym

c

Scientific Title

Study of trans arterial chemo-embolization for primary or metastatic lung cancer

Scientific Title:Acronym

Trans arterial chemo-embolization for lung cancer

Region

Japan


Condition

Condition

Stage III/IV lung cancer or metastatic lung cancer, which are unresectable and refractory to standard chemotherapy

Classification by specialty

Hematology and clinical oncology Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

For non-resectable stage III/IV lung cancer or metastatic lung cancer, which are located at mediastinum or lung hilum and refractory to standard chemotherapy, or those tumors in elderly patients, trans arterial cheemo-embolization via bronchial artery is conducted, of which efficacy and prognosis are investigated.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

For non-resectable stage III/IV lung cancer or metastatic lung cancer, which are located at mediastinum or lung hilum and refractory to standard chemotherapy, or those tumors in elderly patients, trans arterial cheemo-embolization via bronchial artery is conducted each 3 weeks with 3 courses at minimum, of which efficacy and prognosis are investigated.

Key secondary outcomes

Accidental embolization at the non-target organs is investigated.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Trans arterial chemo-embolization is repeated evcery 3 weeks in principle, and is conducted 3 times at minimum.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

10 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Mediasitnal and/or hilar tumors which are unresectablea and refbractory to standard chemotherapy.
2. Standard chemotherapy is not available because of elderly and complications.
3. Even having multiple metastatic lesions, long-term survival could be expected if the mediastinal or hilar tumors are shrunk.
4. Patients who agree for the risk and long-teerm forecast.

Key exclusion criteria

Patients with anaphylaxis for contrast medium.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hirooaki
Middle name
Last name Nomori

Organization

Kashiwa Kousei General Hospital

Division name

Department of Thoracic Surgery

Zip code

277-851

Address

617 Shikoda, Kashiwa City

TEL

0471-45-1111

Email

hnomori@qk9.so-net.ne.jp


Public contact

Name of contact person

1st name Hiroaki
Middle name
Last name Nomori

Organization

Kashiwa Kousei General Hospital

Division name

Department of Thoracic Surgery

Zip code

277-851

Address

617 Shikoda, Kashiwa City

TEL

0471-45-1111

Homepage URL


Email

hnomori@qk9.so-net.ne.jp


Sponsor or person

Institute

Kashiwa Kousei General Hospital,
Department of Thoracic Surgery

Institute

Department

Personal name



Funding Source

Organization

Kashiwa Kousei General Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kashiwa Kousei General Hospital

Address

617 Shikoda, Kashiwa City,Chiba

Tel

0471-45-1111

Email

hnomori@qk9.so-net.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 10 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 09 Month 30 Day

Date of IRB

2019 Year 09 Month 30 Day

Anticipated trial start date

2019 Year 09 Month 30 Day

Last follow-up date

2029 Year 10 Month 01 Day

Date of closure to data entry

2029 Year 10 Month 01 Day

Date trial data considered complete

2029 Year 10 Month 01 Day

Date analysis concluded

2029 Year 10 Month 01 Day


Other

Other related information



Management information

Registered date

2019 Year 10 Month 02 Day

Last modified on

2019 Year 10 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043527


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name